# Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

> **NCT01554618** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 84 (actual)

## Conditions studied

- Children and Adolescent With Type 2 Diabetes

## Interventions

- **DRUG:** Exenatide Once Weekly
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01554618
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-02
- **Primary completion:** 2020-05-06
- **Final completion:** 2021-05-05
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01554618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01554618, "Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01554618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*